But Dr. Joseph McGowan, HIV services medical director at Northwell Health, said he hadn’t seen a noticeable decline in STI ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

We need to diversify our HIV workforce with new roles that align with the health and well-being ... scientist with clinical ...

The U.S. syphilis epidemic slowed dramatically last year, gonorrhea cases fell and chlamydia cases remained below prepandemic levels.

From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

Georgia continues to see a high rate of sexually transmitted diseases, despite a drop in case numbers nationally, according to the CDC ...

“We are talking about sex and drugs—two topics that people call taboo,” said Brigitte Quenum, UNAIDS Regional Team Lead for ...

Another factor may have been an increase in the number of health workers testing people for infections, doing contact tracing and connecting people to treatment ... in new infections — fewer than ...

Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...

Although sexually transmitted infections are still at an epidemic level in the US, scientists at the US Centers for Disease ...

and these new data continue to reinforce the efficacy and safety of Dovato, a two-drug regimen. “The findings from the DOLCE ...